Acurx Pharmaceuticals Q1 2025: Net Loss Narrows to $17.03M
Ticker: ACXP · Form: 10-Q · Filed: May 12, 2025 · CIK: 1736243
| Field | Detail |
|---|---|
| Company | Acurx Pharmaceuticals, Inc. (ACXP) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, net-loss, warrants
TL;DR
Acurx Q1 net loss down to $17M from $22M last year. Warrants issued.
AI Summary
Acurx Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported a net loss of $17.03 million for the three months ended March 31, 2025, compared to a net loss of $22.40 million for the same period in the prior year. The filing also details various warrant issuances and related financial inputs during the first quarter of 2025.
Why It Matters
The narrowing net loss suggests improved financial performance for Acurx Pharmaceuticals, which could impact investor confidence and future funding opportunities.
Risk Assessment
Risk Level: medium — The company continues to report significant net losses, indicating ongoing financial challenges and reliance on external funding.
Key Numbers
- $17.03M — Net Loss (Q1 2025) (Represents a decrease from the prior year's Q1 net loss.)
- $22.40M — Net Loss (Q1 2024) (Prior year period for comparison.)
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Filer of the 10-Q report
- March 31, 2025 (date) — End of the reporting period
- $17.03 million (dollar_amount) — Net loss for the three months ended March 31, 2025
- $22.40 million (dollar_amount) — Net loss for the three months ended March 31, 2024
- 2025-01-06 (date) — Date of warrant issuance related inputs
- 2025-03-06 (date) — Date of warrant issuance related inputs
FAQ
What was Acurx Pharmaceuticals' net loss for the first quarter of 2025?
Acurx Pharmaceuticals reported a net loss of $17.03 million for the three months ended March 31, 2025.
How does the Q1 2025 net loss compare to the same period in 2024?
The net loss for Q1 2025 was $17.03 million, a decrease from $22.40 million for the same period in 2024.
What types of financial instruments are mentioned in relation to specific dates in early 2025?
The filing mentions Series F Warrants and Over-Allotment Options with associated measurement inputs (share price, risk-free interest rate, price volatility, expected term) for dates such as January 6, 2025, and March 6, 2025.
What is the fiscal year end for Acurx Pharmaceuticals?
Acurx Pharmaceuticals' fiscal year ends on December 31st.
Where is Acurx Pharmaceuticals, Inc. headquartered?
Acurx Pharmaceuticals, Inc. is located at 259 Liberty Avenue, Staten Island, NY 10305.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Acurx Pharmaceuticals, Inc. (ACXP).